S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
NASDAQ:VTVT

vTv Therapeutics (VTVT) News Today

$0.46
+0.01 (+2.22%)
(As of 09/27/2023 ET)
Compare
Today's Range
$0.44
▼
$0.46
50-Day Range
$0.42
▼
$0.74
52-Week Range
$0.41
▼
$1.05
Volume
51,916 shs
Average Volume
135,219 shs
Market Capitalization
$48.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media
SourceHeadline
finance.yahoo.com logoCANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19
finance.yahoo.com - September 27 at 10:38 AM
finance.yahoo.com logoCantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer
finance.yahoo.com - September 26 at 11:35 AM
MarketBeat logovTv Therapeutics (NASDAQ:VTVT) Now Covered by StockNews.com
americanbankingnews.com - September 24 at 3:20 AM
finance.yahoo.com logoCANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA
finance.yahoo.com - September 18 at 10:26 AM
finance.yahoo.com logoIs vTv Therapeutics Inc (VTVT) Modestly Undervalued?
finance.yahoo.com - August 24 at 6:06 PM
finance.yahoo.com logovTv Therapeutics reports $5.6 million net loss as prepares for reverse stock split to remain on Nasdaq
finance.yahoo.com - August 16 at 4:23 PM
finanznachrichten.de logovTv Therapeutics Inc.: vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update
finanznachrichten.de - August 12 at 8:18 AM
finance.yahoo.com logovTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - August 11 at 5:16 PM
finance.yahoo.com logoCantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer
finance.yahoo.com - August 10 at 11:34 AM
msn.com logoNearly half of U.S. adults want weight-loss drugs – KFF poll
msn.com - August 6 at 10:58 PM
finance.yahoo.com logoVTVT - vTv Therapeutics Inc.
finance.yahoo.com - July 12 at 12:55 PM
msn.com logovTv Therapeutics Inc - (VTVT) Price Target Decreased by 33.33% to 2.04
msn.com - July 6 at 10:29 PM
marketwatch.com logovTv Therapeutics Partner Licenses Exclusive Rights to Intellectual Property for Azeliragon
marketwatch.com - June 16 at 12:16 PM
tmcnet.com logovTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a
tmcnet.com - June 16 at 12:16 PM
finance.yahoo.com logovTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline
finance.yahoo.com - June 16 at 12:16 PM
finance.yahoo.com logoCANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON
finance.yahoo.com - June 15 at 10:25 AM
bizjournals.com logoAs it advances its Type 1 Diabetes treatment, vTv Therapeutics increases cash position, decreases net loss in Q1
bizjournals.com - June 6 at 4:47 PM
finance.yahoo.com logovTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals
finance.yahoo.com - May 24 at 2:17 PM
finanznachrichten.de logovTv Therapeutics Inc.: vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update
finanznachrichten.de - May 12 at 8:33 AM
finance.yahoo.com logovTv Therapeutics Insider Ups Holding During Year
finance.yahoo.com - May 12 at 8:33 AM
finance.yahoo.com logovTv Therapeutics Insider Ups Holding During Year \
finance.yahoo.com - May 12 at 8:33 AM
finance.yahoo.com logovTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - May 11 at 8:53 PM
morningstar.com logovTv Therapeutics Inc Class A
morningstar.com - April 28 at 9:27 PM
finance.yahoo.com logoCantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19
finance.yahoo.com - April 20 at 12:51 PM
msn.com logoPromising Upsides on these Biotech Penny Stocks
msn.com - April 18 at 6:07 PM
marketbeat.com logoPromising Upsides on these Biotech Penny Stocks (VTVT)
marketbeat.com - April 18 at 8:17 AM
finance.yahoo.com logo3 Pharma Stocks That Could Benefit from Global Healthcare Trends
finance.yahoo.com - March 25 at 9:48 AM
finance.yahoo.com logovTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
finance.yahoo.com - March 6 at 7:21 PM
finance.yahoo.com logoCantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases
finance.yahoo.com - March 6 at 8:21 AM
finance.yahoo.com logovTv Therapeutics (NASDAQ:VTVT) investors are sitting on a loss of 88% if they invested five years ago
finance.yahoo.com - March 3 at 6:34 AM
finance.yahoo.com logoCantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma
finance.yahoo.com - February 27 at 11:27 PM
finance.yahoo.com logoElizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics
finance.yahoo.com - February 1 at 8:33 PM
reuters.com logoVTVT.PH - | Stock Price & Latest News | Reuters
reuters.com - January 31 at 11:39 PM
marketbeat.com logoFY2023 Earnings Forecast for vTv Therapeutics Inc. (NASDAQ:VTVT) Issued By Cantor Fitzgerald
marketbeat.com - January 23 at 1:43 AM
finance.yahoo.com logoPrivate equity firms in vTv Therapeutics Inc. (NASDAQ:VTVT) are its biggest bettors, and their bets paid off as stock gained 21% last week
finance.yahoo.com - January 20 at 2:47 PM
bizjournals.com logovTv Therapeutics names biotechnology industry veteran Steven Tuch as CFO
bizjournals.com - January 12 at 9:26 AM
finance.yahoo.com logoCANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA
finance.yahoo.com - January 9 at 10:32 AM
forbes.com logoVtv Therapeutics
forbes.com - January 5 at 2:37 PM
finance.yahoo.com logovTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer
finance.yahoo.com - December 13 at 11:44 AM
finance.yahoo.com logoTrade Alert: The Independent Director Of vTv Therapeutics Inc. (NASDAQ:VTVT), John Fry, Has Just Spent US$51k Buying A Few More Shares
finance.yahoo.com - December 3 at 8:26 AM
benzinga.com logovTv Therapeutics Board Member Makes $50K Stock Purchase
benzinga.com - December 1 at 11:23 AM
marketbeat.com logovTv Therapeutics (NASDAQ:VTVT) Research Coverage Started at StockNews.com
marketbeat.com - November 17 at 9:00 AM
finance.yahoo.com logoThree months after leadership change, vTv Therapeutics reports cash of $15.3 million and net loss of $4.3 million in Q3
finance.yahoo.com - November 15 at 5:50 PM
finanznachrichten.de logovTv Therapeutics Inc.: vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update
finanznachrichten.de - November 11 at 1:25 PM
finance.yahoo.com logovTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - November 10 at 10:23 PM
finance.yahoo.com logoVTv Therapeutics (VTVT) Reports Q3 Loss, Lags Revenue Estimates
finance.yahoo.com - November 10 at 10:23 PM
finance.yahoo.com logovTv Therapeutics (NASDAQ:VTVT shareholders incur further losses as stock declines 17% this week, taking five-year losses to 84%
finance.yahoo.com - September 23 at 8:34 AM
seekingalpha.com logoVTVT vTv Therapeutics Inc.
seekingalpha.com - September 22 at 8:28 PM
finance.yahoo.com logoThis Diabetes Drug's 'Licensing Opportunity Is Underappreciated,' Analyst Says
finance.yahoo.com - August 19 at 8:04 PM
bizjournals.com logoAfter third leadership change in less than a year, vTv Therapeutics Inc. reports $3.2 million net loss in Q2
bizjournals.com - August 19 at 9:19 AM
Get vTv Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter.



VTVT Media Mentions By Week

VTVT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

VTVT
News Sentiment
▼
0.87

0.86
▲
Average
Medical
News Sentiment

VTVT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

VTVT Articles
This Week
▼
4

1
▲
VTVT Articles
Average Week

Get vTv Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:VTVT) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -